Publications, Pharmaceutical

Aptar Pharma Q&A on trends and challenges in nasal drug delivery

Nasal drug delivery is currently the focus of considerable drug development activity.

This Q&A takes a detailed look at the nasal drug delivery landscape and the potential of this route for the delivery of vaccines and therapeutics for COVID-19, for nose-to-brain drug delivery and for improving the accessibility of emergency medications. Key challenges associated with the development of nasal drug products are outlined along with factors impacting device design and selection.
The regulatory landscape is also considered. Barriers to the development of nasal drug delivery products are examined but it is concluded that the route has a bright future with considerable potential to address currently unmet therapeutic needs.

Download the Q&A
Author(s): Dr Julie D. Suman
21 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

10 Dec 2020

Nasal Drug Delivery: Past, Present and Future Perspectives

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
30 Nov 2020

Exploring the role of EI in partnerships for OINDP development

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions, Sustainability, Innovation & Insights

Read More
5 Nov 2020

The Need to Scale Up Digital Health in the Post-Covid World

Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights, Device Innovations, Brand Differentiation

Read More
6 Oct 2020

Using Bioequivalence and Particle Size Distribution to Develop OINDPs

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
1 18 19 20 21 22 25

Request Access

Close

Requesting access to Aptar Pharma Q&A on trends and challenges in nasal drug delivery.

  • This field is for validation purposes and should be left unchanged.
Back To Top